ArticleAmerican journal of preventive cardiology2025
Cholesterol management in US adults with ASCVD in the Family Heart Database® during 2022-23: Current state of care and opportunities for improvement.
Article in American journal of preventive cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adults with atherosclerotic cardiovascular disease (ASCVD) have increased risk of recurrent events and need optimized low density lipoprotein-cholesterol (LDL-C) lowering therapy, yet the factors contributing to LDL-C management are not well understood. Methods: This cohort study of the national Family Heart Database aims to characterize the current state of LDL-C management in US adults with ASCVD. Adults with ASCVD and ≥1 medication claim yearly and ≥1 LDL-C measure during 2022 or 2023 were included. The lowest LDL-C level reported (<55 mg/dL; 55-69 mg/dL; ≥70 mg/dL); intensity of dispensed LDL-C therapy (high intensity; low/moderate intensity; none); and duration of dispensed LDL-C therapy (>20 of 24 months; 13 to 20 months; >0 to <13 months; none) were characterized. Results: The database included adults ( Conclusions and Relevance: In this cohort of 3.6 million US adults with ASCVD there was a substantial gap between guideline recommended LDL-C management and clinical care. Several factors contributed to this gap including low use of nonstatin LDL-C therapies in this high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.